NCT06472635View on ClinicalTrials.gov

a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study

Active, not recruitingOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions
The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma
Trial Locations (1)

3210002

The first affiliated hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER